Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

Abstract Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear. In this retrospective study, we evaluated the clinical outcomes of patients with mCRC trea...

Full description

Bibliographic Details
Main Authors:	Hung‐Chih Hsu, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin, Tsai-Sheng Yang
Format:	Article
Language:	English
Published:	Wiley 2019-07-01
Series:	Cancer Medicine
Subjects:	anti‐EGFR/anti‐VEGF biological therapy sequence metastatic colorectal cancer survival
Online Access:	https://doi.org/10.1002/cam4.2235

Similar Items

Kras in metastatic colorectal cancer
by: A Wicki, et al.
Published: (2010-11-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
by: Ting-Yu Chiang, et al.
Published: (2023-03-01)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
by: Florian Huemer, et al.
Published: (2018-01-01)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
by: Chen DT, et al.
Published: (2019-02-01)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01)

Intravítrea de bevacizumab en el edema macular secundario a oclusión venosa de rama retiniana
by: Caridad Chiang Rodríguez, et al.

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
by: Ioana Mihaela Dinu, et al.
Published: (2023-02-01)

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
by: Qian Wu, et al.
Published: (2022-08-01)

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
by: Lola-Jade Palmieri, et al.
Published: (2022-03-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
by: Amy eBarone, et al.
Published: (2013-04-01)

KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report
by: Qunli Xiong, et al.
Published: (2022-05-01)

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
by: Ralf-Dieter Hofheinz, et al.
Published: (2022-07-01)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
by: Dalyong Kim, et al.
Published: (2017-11-01)

Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
by: Yi‐Hsin Liang, et al.
Published: (2023-07-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Yi-Chia Su, et al.
Published: (2022-04-01)

Short-term intraocular pressure changes after intravitreal bevacizumab injection
by: Ali Dehghani, et al.
Published: (2014-08-01)

Short-term intraocular pressure changes after intravitreal bevacizumab injection
by: Ali Dehghani, et al.
Published: (2014-06-01)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
by: Hung-Chih Hsu, et al.
Published: (2018-09-01)

Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
by: Muyou Tian, et al.
Published: (2023-11-01)

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
by: Najah Albadari, et al.
Published: (2024-01-01)

Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
by: Erin M. Dunbar, et al.
Published: (2012-06-01)

Monoclonal antibodies in cervical malignancy-related HPV
by: Parisa Shiri Aghbash, et al.
Published: (2022-10-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Inyección intravítrea de bevacizumab vs. acetato de triamcinolona en el edema macular secundario a oclusión de rama venosa retiniana
by: Caridad Chiang Rodríguez, et al.

The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: experimental in-vivo electron microscopic study in intact versus vitrectomized eyes
by: Kocak Nilufer, et al.
Published: (2010-12-01)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
by: Martin S. Schulz, et al.
Published: (2022-03-01)

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer
by: Chien-Yu Lin, et al.
Published: (2023-06-01)

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
by: Davide Ciardiello, et al.
Published: (2023-04-01)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
by: Liu J, et al.
Published: (2019-11-01)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
by: Anna Maria Rachiglio, et al.
Published: (2022-02-01)

INTRA VITREOUS BEVACIZUMAB VERSUS OBSERVATION IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
by: Bassam Mubarik, et al.
Published: (2018-09-01)

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
by: Joel Hanhart, et al.
Published: (2017-10-01)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
by: Tamotsu Sagawa, et al.
Published: (2023-06-01)

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
by: J. H. Börner, et al.
Published: (2023-09-01)